LOTTE Biologics Secures Commercial Manufacturing Agreement for Songdo Plant 1
LOTTE Biologics signs its commercial manufacturing agreement for Songdo Plant 1 with a global pharmaceutical company, with production expected to begin in 2027.
Integrated Drug Substance | 18/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy